Elevance Health, Inc. (NYSE:ELV) is one of the largest and most influential health insurance and managed care companies in the United States, serving more than 48 million members across its diverse portfolio of medical, pharmacy, behavioral health, and care management services. Formerly known as Anthem, Inc., the company rebranded to Elevance Health in 2022 to reflect its evolution from a traditional health benefits provider into a comprehensive health solutions enterprise. Headquartered in Indianapolis, Indiana, Elevance operates through a family of brands—including Blue Cross Blue Shield plans in 14 states—and provides an integrated approach to care that combines insurance coverage, digital innovation, and value-based healthcare delivery. Its mission is to improve lives and communities by simplifying healthcare and advancing health beyond traditional coverage models.
The company’s transformation has been driven by its dual-engine structure: its Health Benefits segment, which encompasses its core medical insurance and government-sponsored plans, and Carelon, a fast-growing health services arm that focuses on pharmacy benefits, analytics, behavioral health, and advanced care delivery. CarelonRx, the pharmacy services division within Carelon, manages millions of prescriptions each year, leveraging data-driven insights to optimize medication adherence and reduce healthcare costs. This vertical integration has positioned Elevance at the forefront of a new generation of health enterprises that blend technology, prevention, and coordinated care to deliver better outcomes for patients and employers alike.
Elevance has also strengthened its presence in the government health programs market, particularly within Medicare Advantage, Medicaid, and dual-eligible special needs plans (D-SNPs). The company’s focus on these segments underscores its long-term strategy of balancing growth with margin stability, even as it withdraws from lower-margin areas such as standalone Medicare Part D. With over 2.3 million Medicare Advantage members, Elevance has built a robust platform that caters to seniors and low-income populations through tailored care solutions and community-based partnerships. Its recent move to refine its Medicare footprint highlights its focus on sustainability and disciplined capital deployment amid rising medical cost pressures across the industry.
A Strategic Retrenchment to Protect Margins
Rather than stretching its portfolio across volatile and low-margin sectors, Elevance is doubling down on its most resilient and profitable business lines — namely Medicare Advantage HMO plans and dual-special needs plans (D-SNPs). These segments historically deliver more stable enrollment growth and higher profitability due to tighter cost management and targeted patient populations. The company’s trailing 12-month return on capital stands at 10.4%, well above the industry average of 7.4%, demonstrating its ability to deploy capital efficiently even as competitors tighten their forecasts.
This strategic retrenchment is not an isolated event. It’s part of a larger industry trend where leading insurers are prioritizing margin stability over aggressive top-line expansion. Medical cost ratios across the sector have been trending higher, forcing even giants like UnitedHealth Group and Molina Healthcare to scale back earnings guidance. By exiting underperforming segments early, Elevance aims to position itself ahead of these headwinds and safeguard its long-term earnings trajectory.
CHECK THIS OUT: Tiziana (TLSA) Surges 143% in 2025 and Immuneering (IMRX) Reports 86% 9-Month Survival in Pancreatic Cancer.
Industry-Wide Pressures Highlight Elevance’s Discipline
The healthcare insurance industry is currently navigating one of the most complex operating environments in recent years. Rising utilization rates, higher claim volumes, and adjustments to risk-scoring methodologies have collectively compressed margins. As a result, all major players are reassessing their exposure to the Medicare Advantage program — traditionally a growth engine for the industry.
UnitedHealth Group, for example, slashed its 2025 adjusted EPS forecast to at least $16, abandoning its previous guidance of $26–$26.50, while Molina Healthcare reduced its forecast from $24.50 to $19.00. Elevance also adjusted its expectations, now projecting 2025 adjusted EPS of approximately $30, down from its earlier range of $34.15–$34.85. Although this appears to be a pullback, it reflects conservative guidance amid a shifting reimbursement landscape and rising costs of care delivery.
Despite these short-term adjustments, Elevance’s underlying fundamentals remain stronger than many peers. Its diversified portfolio, robust cash flow, and leading positions in both commercial and government programs give it the flexibility to navigate the ongoing volatility.
Exit from Part D: A Strategic Reset
Elevance’s exit from the standalone Medicare Part D segment marks a significant pivot within the industry. According to KFF data, the company ranks as the sixth-largest standalone Part D provider, and its withdrawal will inevitably reshape the competitive landscape. While this move will reduce consumer options in the short term, it allows Elevance to refocus on its core strengths in integrated care and Medicare Advantage, where it holds distinct competitive advantages.
The exit also comes on the heels of a legal setback regarding its 2025 star ratings, which is expected to cost the insurer approximately $375 million next year. While this poses a near-term challenge, it further underscores the company’s rationale for simplifying its portfolio and reinforcing operational efficiency. By exiting a highly competitive and regulation-heavy segment, Elevance can redeploy capital toward growth opportunities that promise higher returns and better long-term visibility.
Valuation and Investor Perspective
From a valuation standpoint, Elevance Health currently trades at a forward price-to-earnings ratio of 10.06, well below the industry average of 14.90, suggesting the stock remains undervalued relative to peers. This discounted valuation provides a compelling entry point for long-term investors who recognize the company’s resilience and disciplined strategy. With a Value Score of “A” from Zacks Investment Research, Elevance’s fundamentals indicate substantial upside potential once Medicare headwinds normalize.
Shares of ELV have fallen 14.6% year-to-date, compared to the industry’s broader decline of 2.9%, but analysts see this as a temporary correction rather than a fundamental deterioration. The company’s strong capital efficiency, stable cash flows, and ongoing share repurchases could serve as catalysts for a recovery once investor sentiment improves.
A Leaner, More Profitable Future Ahead
As the Medicare Advantage environment grows increasingly complex, Elevance’s focus on core strengths—its Carelon integrated care platform, cost discipline, and profitable HMO and D-SNP lines—positions it for sustainable long-term growth. The company’s decision to streamline its operations is not a retreat but a refinement of strategy, allowing it to emerge from current challenges with a stronger competitive edge.
While the next few quarters may test investor patience, Elevance Health’s combination of efficiency, scale, and financial prudence makes it one of the most strategically positioned players in the managed care sector. As the company adapts to an evolving regulatory and cost landscape, its emphasis on profitability over expansion could ultimately reward shareholders with steady compounding returns once macro conditions stabilize.
READ ALSO: Saudi Arabia Wants CEL-SCI (CVM)’s Multikine Now! and Aligos Therapeutics (ALGS) Doubles Cash to $122.9M.
